Key result
Polidocanol sclerotherapy linked to severe Takotsubo syndrome with 23% LVEF requiring mechanical support.
Why the study?
Takotsubo Syndrome is typically linked to emotional distress but can follow medical procedures, and recognition of its occurrence after sclerotherapy is needed.
Does sclerotherapy with Polidocanol induce Takotsubo Syndrome in patients with pelvic varices?
Case Report (n=1)
Does sclerotherapy with Polidocanol induce Takotsubo Syndrome in patients with pelvic varices?
Sclerotherapy with Polidocanol can trigger severe, rapid-onset Takotsubo Syndrome, highlighting the need for awareness during minimally invasive vascular procedures.
Answers are grounded in this paper and cite their sources.
Polidocanol sclerotherapy may trigger Takotsubo syndrome; this case leaves open causality and generalizability.
Takotsubo Syndrome (TS), also known as stress cardiomyopathy, is an acute, reversible left ventricular dysfunction often triggered by emotional or physical stressors. Although most cases are associated with emotional distress, TS has also been reported following medical procedures. We present the case of a 40-year-old female who developed TS immediately after undergoing sclerotherapy with Polidocanol for pelvic varices. Shortly after the injection, she experienced acute chest pain, dyspnea, tachycardia, and hypertension. Electrocardiography showed T-wave inversion, and echocardiography revealed a severely reduced left ventricular ejection fraction (23%) with apical ballooning. Coronary angiography ruled out obstructive coronary disease, consistent with a diagnosis of Polidocanol-induced Takotsubo Syndrome. The patient required inotropic support in the Intensive Care Unit and an intra-aortic balloon pump, with cardiac recovery within seven days. Although rare, TS should be considered in patients experiencing acute cardiovascular symptoms after sclerotherapy. The pathophysiological mechanisms remain unclear but may involve endothelial irritation, systemic inflammation, and autonomic dysregulation. This specific case is unique due to the patient’s age, the severity of the cardiac dysfunction and the time of symptom onset. Awareness of this complication is crucial for early recognition and appropriate management, particularly in high-risk patients undergoing minimally invasive vascular procedures in an ambulatory care unit. • Takotsubo Syndrome can be triggered by sclerotherapy with Polidocanol • This case highlights severe cardiac dysfunction and rapid symptom onset • Early recognition of Takotsubo Syndrome is crucial for successful management • Awareness of Polidocanol-induced Takotsubo Syndrome is vital in vascular procedures. • Patient experienced full cardiac recovery
No takes yet. Share an insight, caveat, or question.
Detsch et al. (2025) conducted a case report in Takotsubo Syndrome (n=1). Sclerotherapy with Polidocanol was evaluated. Sclerotherapy with Polidocanol induced severe Takotsubo Syndrome with an LVEF of 23% in a 40-year-old female, requiring inotropic support and an intra-aortic balloon pump before full recovery.
Synapse has enriched 10 related papers. Consider them for comparative context: